Our results with pyridostatin provide a strong rationale for testing it in combination with immune blockade drugs (e.g. anti‐PD‐1 or anti‐CTLA4 antibodies) for the treatment of BRCA1/2‐deficient tumours. Here, CTLA4 is linked to neoplasm.